Jill M. Broadfoot
2021 - aTYR PHARMA
In 2021, Jill M. Broadfoot earned a total compensation of $917.4K as Chief Financial Officer at aTYR PHARMA, a 31% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $173,282 |
|---|---|
| Option Awards | $355,683 |
| Salary | $376,723 |
| Other | $11,755 |
| Total | $917,443 |
Broadfoot received $376.7K in salary, accounting for 41% of the total pay in 2021.
Broadfoot also received $173.3K in non-equity incentive plan, $355.7K in option awards and $11.8K in other compensation.
Rankings
In 2021, Jill M. Broadfoot's compensation ranked 9,063rd out of 12,415 executives tracked by ExecPay. In other words, Broadfoot earned more than 27.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,063 out of 12,415 | 27th |
Division Manufacturing | 4,025 out of 5,508 | 27th |
Major group Chemicals And Allied Products | 1,770 out of 2,378 | 26th |
Industry group Drugs | 1,575 out of 2,099 | 25th |
Industry Biological Products, Except Diagnostic Substances | 344 out of 449 | 23rd |
Source: SEC filing on March 22, 2022.
Broadfoot's colleagues
We found two more compensation records of executives who worked with Jill M. Broadfoot at aTYR PHARMA in 2021.
News
aTYR PHARMA CEO Sanjay Shukla's 2023 pay falls 46% to $1.3M
April 5, 2024
aTYR PHARMA CEO Sanjay Shukla's 2021 pay jumps 75% to $1.9M
March 22, 2022
aTYR PHARMA CEO Sanjay Shukla's 2020 pay jumps 63% to $1.1M
March 23, 2021
aTYR PHARMA CEO Sanjay Shukla's 2019 pay falls 52% to $664K
April 2, 2020
aTYR PHARMA CEO Sanjay Shukla's 2018 pay falls 36% to $1.4M
March 28, 2019